Table 2.
Outcomes associated with continuous use of or deprescribed traditional benzodiazepines.
| Outcome | Continuous use | Deprescribed | Impact of deprescribing sHR (95%CI) |
p value |
|---|---|---|---|---|
| Death, % Time to event, years (IQR) |
22.9 1.6 (0.7-3.1) |
23.3 1.6 (0.6-3.1) |
- |
1.0 |
| Decompensation | ||||
| Any decompensation, % Time to event, years (IQR) |
16.4 1.3 (0.5-2.4) |
17.5 1.1 (0.5-2.1) |
1.08 (0.87-1.34) |
0.5 |
| Hepatic encephalopathy, % Time to event, years (IQR) |
7.6 1.5 (0.6-2.4) |
7.3 1.1 (0.5-2.5) |
0.96 (0.69-1.35) |
0.8 |
| Ascites, % Time to event, years (IQR) |
13.9 1.5 (0.4-2.7) |
14.0 1.2 (0.5-2.2) |
1.02 (0.80-1.30) |
0.9 |
| Injuries | ||||
| Fractures, % Time to event, years (IQR) |
20.6 1.2 (0.4-2.5) |
20.5 1.3 (0.4-2.5) |
0.98 (0.80-1.20) |
0.8 |
| Falls, % Time to event, years (IQR) |
21.6 1.3 (0.6-2.5) |
21.3 1.6 (0.6-2.9) |
0.96 (0.79-1.16) |
0.7 |
| Intracranial hemorrhage Time to event, years (IQR) |
2.1 1.5 (0.8-3.4) |
2.0 2.9 (0.7-3.8) |
0.90 (0.47-1.14) |
0.7 |
| Other | ||||
| Alcohol-hospitalizations, % Time to event, years (IQR) |
21.9 0.9 (0.4-1.9) |
22.1 0.9 (0.4-1.9) |
0.98 | 0.8 |
The raw proportions for each outcome are listed as percentages and the times to event are listed as median days. All outcomes are then assessed using Fine-Gray competing-risk regression to yield sHRs. The competing-risk analysis demonstrates the risk of death as a competing risk with each outcome. Variceal bleeding is not evaluated for insufficient events.
sHR, subdistribution hazard ratio.